Beyond malignant disease, anti-CD20 therapies play an important role in the treatment of inflammatory and autoimmune diseases. This review will seek to explore the physiological and pathophysiological underpinnings of CD20 monoclonal antibodies (mAbs), the history of their development, their pharmacological properties and the difference between ...

CD20 monoclonal antibodies are targeted against B-cell antigens, and were originally developed to treat B-cell Non-Hodgkin's lymphoma. For ratings, users were asked how effective they …

The first therapeutic anti-CD20 mAb, rituximab, is a murine–human chimera to which many patients develop antibodies and/or experience infusion-related reactions. A second generation of anti-CD20 mAbs has been designed to be more effective, better tolerated, and of lower immunogenicity.

Introduction: The introduction of anti-CD20 monoclonal antibody therapy with rituximab in the 1990s greatly improved outcomes for patients with B-cell malignancies.

Anti-CD20 mAbs have emerged as an essential treatment option for patients with relapsing MS. Clinicians must be aware that anti-CD20 mAbs differ in their structures, target epitopes, dosing regimens, route of administration, and mechanisms of B cell depletion.

2012年5月24日 · The oncologist recommends treatment with the anti-CD20 monoclonal antibody rituximab in combination with a chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and...

We summarize the rationale regarding the use of anti-CD20 therapies and the results of the main randomized controlled trials and observational studies investigating the efficacy and safety profile of rituximab, ocrelizumab, ofatumumab and ublituximab.

In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab.

5 天之前 · The anti-CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab, and ublituximab are used to treat multiple sclerosis, and the anti-CD19 monoclonal antibody inebilizumab is used to treat neuromyelitis optica spectrum disorder; they work by binding to B cells and causing them to be eliminated. These therapeutic antibodies were designed to have …

Novel anti-CD20 mAbs have structural and pharmacodynamic characteristics that distinguish them from rituximab. In this section, we examine these characteristics and their mechanistic consequences in preparation for later discussion of their clinical consequences.